Is Neuren Pharmaceuticals (ASX: NEU) Poised to Reclaim Higher Levels After Forming a Higher Low?
Neuren Pharmaceuticals (ASX: NEU) is a rare-disease biotech generating revenue from DAYBUE while advancing NNZ-2591. After declines from regulatory and guidance setbacks, improving US rollout and technical strength suggest a recovery, with the stock forming higher lows and testing key resistance levels.
Telix Pharmaceuticals (ASX: TLX) Rebounds From Heavy Sell-Off Reignites Investor Optimism
Telix Pharmaceuticals (ASX: TLX) is recovering after a sharp biotech sell-off driven by regulatory and legal concerns. Renewed investor confidence follows strong revenue growth, progress in Phase 3, and a Regeneron partnership, with FY2026 revenue nearing US$1 billion and pipeline milestones advancing.
Is Alterity Therapeutics (ASX: ATH) Stabilising After Volatility at a Key Technical Level?
Alterity Therapeutics (ASX: ATH) is advancing its lead neurodegeneration drug, ATH434, toward Phase 3 trials. Following positive clinical data and a 1-for-50 share consolidation, the stock is holding key technical support around 0.450, awaiting a potential upside breakout.
Is Paradigm Biopharmaceuticals (ASX: PAR) Bottoming Out After Its Prolonged Downtrend?
Paradigm Biopharmaceuticals (ASX: PAR) is an Australian late-stage biotech developing injectable PPS, mainly for osteoarthritis. Its shares have fallen more than 95% since 2020 amid trial delays, dilution and losses, with August 2026 Phase 3 interim data now the key catalyst.
Dimerix (ASX: DXB) Slides Toward $0.19 After Volatile Phase III Trial-Driven Swings
Dimerix slipped toward $0.19 after volatile trading driven by its Phase 3 ACTION3 trial. The biotech continues to swing on sentiment as investors react to clinical updates, balancing long-term DMX-200 hopes against no-revenue uncertainty and regulatory timelines.
Is Breakout in Clinuvel Pharmaceuticals (ASX: CUV) Signalling a Sustainable Bullish Reversal?
CLINUVEL is a global photomedicine group commercialising SCENESSE for rare disorders while advancing vitiligo, ACTH and porphyria programs. Recent share strength reflects EMA vitiligo progress, stronger pipeline visibility and Nasdaq listing plans, though Phase III, regulatory and competition risks remain.